Iqbal J. Hussain Sells 12,000 Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 12,000 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $14.02, for a total value of $168,240.00. Following the transaction, the general counsel now owns 105,386 shares of the company's stock, valued at $1,477,511.72. The trade was a 10.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Stock Down 5.4%

NASDAQ CNTA traded down $0.77 on Wednesday, hitting $13.43. The company had a trading volume of 779,371 shares, compared to its average volume of 729,021. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37. The company's fifty day moving average price is $12.76 and its 200-day moving average price is $14.79. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $8.46 and a 12-month high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. As a group, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CNTA. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. Morgan Stanley restated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Needham & Company LLC initiated coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price target on the stock. Finally, Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $27.89.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd lifted its holdings in Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in Centessa Pharmaceuticals in the 1st quarter valued at $47,000. Barclays PLC boosted its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Centessa Pharmaceuticals during the fourth quarter worth $162,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.